Skip to content
Screener

PTC Therapeutics PTCT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$11.72B+57.2%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$326.28M+112%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$518.52M+14.1%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.5M

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.91B+45.3%
Enterprise value$5.47B+58.8%
P/E7.3×
P/S7.2×+4.8×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemMarch 31, 2026December 31, 2025
Total liabilities3,049,5693,104,080
Stockholders’ deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025.8180
Additional paid-in capital2,778,0262,748,335
Accumulated other comprehensive income8,46610,501
Accumulated deficit(2,967,038)(2,964,229)
Total stockholders’ deficit(180,465)(205,313)
Total liabilities and stockholders’ deficit$2,869,104$2,898,767

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's total liabilities & equity?
PTC Therapeutics (PTCT) reported total liabilities & equity of $2.87B in Q1 2026.
How has PTC Therapeutics's total liabilities & equity changed year-over-year?
PTC Therapeutics's total liabilities & equity increased by 8.0% year-over-year, from $2.66B to $2.87B.
What is the long-term trend for PTC Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), PTC Therapeutics's total liabilities & equity has grown at a 5.6% compound annual growth rate (CAGR), from $2.21B to $2.9B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about PTC Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude